Beschreibung
Experimental evidence from animal models of neuroimmune disorders showing the effects of specific CAM therapies on Th17 cell frequency and disease severity scores.
Figure 5
ChartSource Paper
The Role of Th17 in Neuroimmune Disorders: Target for CAM Therapy. Part II.Evidence-based complementary and alternative medicine : eCAM (2011)
PMID: 19622601
DOI: 10.1093/ecam/nep063
Cite This Figure
![Figure 5: Experimental evidence from animal models of neuroimmune disorders showing the effects of specific CAM therapies on Th17 cell frequency and disease severity scores.]() > Source: Aristo Vojdani et al. "The Role of Th17 in Neuroimmune Disorders: Target for CAM Therapy. Part II.." *Evidence-based complementary and alternative medicine : eCAM*, 2011. PMID: [19622601](https://pubmed.ncbi.nlm.nih.gov/19622601/)
<figure> <img src="" alt="Experimental evidence from animal models of neuroimmune disorders showing the effects of specific CAM therapies on Th17 cell frequency and disease severity scores." /> <figcaption>Figure 5. Experimental evidence from animal models of neuroimmune disorders showing the effects of specific CAM therapies on Th17 cell frequency and disease severity scores.<br> Source: Aristo Vojdani et al. "The Role of Th17 in Neuroimmune Disorders: Target for CAM Therapy. Part II.." <em>Evidence-based complementary and alternative medicine : eCAM</em>, 2011. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/19622601/">19622601</a></figcaption> </figure>